Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 10Urinary Bladder Neoplasms 3Stomach Neoplasms 3Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Uveal Melanoma 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Rectal Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Carcinoma, Basal Cell 2Advanced Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Spinocerebellar Degenerations 1Sarcoma 1

Interventions

sintilimab 2pembrolizumab 2Bevacizumab 2vicriviroc 1spartalizumab 1relatlimab 1dabrafenib 1atezolizumab 1Tiragolumab 1Nivolumab 1Immune Checkpoint Inhibitors 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Spinocerebellar Degenerations × relatlimab × Clear all
NCT03642067 2025-06-15

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
59 enrolled 11 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡